Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of R-406. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK known ✓ | P43405 | 13/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | TYRO3 | Q06418 | 2/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.83 |
| ▸ | PLK4 | O00444 | 3/20 | 0.83 |
| ▸ | AURKA | O14965 | 3/20 | 0.83 |
| ▸ | RET | P07949 | 3/20 | 0.83 |
| ▸ | FLT3 | P36888 | 3/20 | 0.83 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.83 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.83 |
| ▸ | MST1R | Q04912 | 3/20 | 0.83 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.83 |
| ▸ | KDR | P35968 | 3/20 | 0.83 |
| ▸ | EGFR | P00533 | 3/20 | 0.83 |
| ▸ | ITK | Q08881 | 3/20 | 0.83 |
| ▸ | JAK3 | P52333 | 3/20 | 0.83 |
| ▸ | ULK1 | O75385 | 3/20 | 0.83 |
| ▸ | STK16 | O75716 | 2/20 | 0.83 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.83 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-406 SCHEMBL30530501 | 1.00 | ADORA3 (1.00) | ADORA3TYRO3SYKPTK2PLK4 | |
| R-406 SCHEMBL1200144 | 0.91 | SYK (1.00) | ADORA3TYRO3SYKPTK2PLK4 | |
| R-406 SCHEMBL29358236 | 0.91 | SYK (1.00) | ADORA3TYRO3SYKPTK2PLK4 | |
| SCHEMBL1383686 | 0.87 | SYK (0.89) | ADORA3TYRO3SYKPTK2PLK4 | |
| R-406 SCHEMBL12903997 | 0.87 | SYK (0.92) | ADORA3TYRO3SYKPTK2PLK4 | |
| SCHEMBL2627469 | 0.86 | SYK (0.91) | ADORA3TYRO3SYKPTK2PLK4 | |
| R-406 SCHEMBL12903982 | 0.86 | SYK (0.91) | ADORA3TYRO3SYKPTK2PLK4 | |
| R-406 SCHEMBL12904000 | 0.86 | SYK (0.89) | ADORA3TYRO3SYKPTK2PLK4 | |
| SCHEMBL11937326 | 0.85 | SYK (0.87) | ADORA3TYRO3SYKPTK2PLK4 | |
| R-406 SCHEMBL12903973 | 0.84 | SYK (0.86) | ADORA3TYRO3SYKPTK2PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115700-A1 | CANCER TREATMENT COMBINATIONS | UNIV CALIFORNIA (US) | 2024-04-11 | — | — | US | disclosed |
| US-11654193-B2 | Cancer treatment combinations | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-23 | — | — | US | disclosed |
| CN-111346101-B | Application of TAMATINIB in preparation of medicine for treating glioma | 中山大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-111346096-B | Pharmaceutical composition for preventing or treating glioma | 中山大学 | 2022-11-22 | — | — | CN | disclosed |
| EP-3936141-A2 | ANTI-SENESCENCE COMPOUNDS AND USES THEREOF | Erasmus University Rotterdam Medical Center (NL) | 2022-01-12 | — | — | EP | disclosed |
| EP-3247375-B1 | ANTI-SENESCENCE COMPOUNDS AND USES THEREOF | UNIV ERASMUS MED CT ROTTERDAM (NL) | 2021-08-04 | — | — | EP | disclosed |
| US-20210038716-A1 | CANCER TREATMENT COMBINATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-02-11 | — | — | US | disclosed |
| US-10688181-B2 | Cancer treatment combinations | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-06-23 | — | — | US | disclosed |
| EP-3024489-B1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND BETA-2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES | ALMIRALL SA (ES) | 2020-02-19 | — | — | EP | disclosed |
| EP-2961407-B1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH 2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2018-04-11 | — | — | EP | disclosed |
| EP-2118100-A1 | NEW 3- ([1,2,4] TRIAZOLO [4,3-A] PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | Almirall, S.A. (ES) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009132774-A1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P39 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S. A. (ES) | 2009-11-05 | — | — | WO | disclosed |
| EP-2113503-A1 | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-11-04 | — | — | EP | disclosed |
| WO-2009124692-A1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | ALMIRALL, S.A. (ES) | 2009-10-15 | — | — | WO | disclosed |
| EP-2108641-A1 | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-10-14 | — | — | EP | disclosed |
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| WO-2008131922-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008107125-A1 | NEW 3-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-09-12 | — | — | WO | disclosed |
| EP-1922313-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | Laboratorios Almirall, S.A. (ES) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007017096-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA3 | SYK 2537/4885ADORA3 3/4885TYRO3 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.